22Nd Century Stock Price, News & Analysis

22nd Century Group (NYSE American: XXII) has announced a new partnership with a leading tobacco exporter, prompting increased investment in production and testing equipment, as well as staff hiring at its North Carolina facility. The company is positioning itself for the global launch of its VLN® reduced nicotine cigarettes, anticipating FDA authorization soon. Improved testing capabilities are expected to lower production costs significantly. The firm is also seeking to expand its distribution channels.

22nd Century Group, with ticker XXII, announced a live webcast on August 5, 2021, at 10:00 AM ET to discuss its second quarter 2021 results. The company will release its results on the same day at 6:00 AM ET. CEO James A. Mish, COO Michael Zercher, and CFO John Franzino will present the results and discuss growth opportunities in the $1.3 trillion addressable market. An interactive Q&A session will follow. Interested parties can access the webcast via the company’s Investor Relations website. 22nd Century focuses on reducing tobacco harm and advancing hemp/cannabis research.

22nd Century Group (NYSE American: XXII) has established strategic partnerships with leading commercial-scale plant breeders, which will enhance its capabilities in alkaloid-based plant breeding and cultivation. These collaborations are aimed at optimizing development cycles from 7-10 years to just 2 years, crucial for meeting the growing demand for stable hemp/cannabis genetics. The company anticipates monetizing its new plant lines and existing intellectual property in the second half of 2021, signaling multiple revenue streams ahead.

22nd Century Group, Inc. (NYSE American: XXII) has acquired Needle Rock Farms in Colorado, valued at $2.2 million, as part of a restructuring agreement with Panacea Life Sciences. The deal includes exchanging a $7 million note for ownership and a new $4.3 million note secured by Panacea’s operations building, appraised at $10.7 million. Additionally, $7 million in Series B Preferred Stock will be converted into 91 million shares of Exactus, Inc.. This strategic move aims to enhance 22nd Century's cannabis capabilities and generate revenue by the second half of 2021.

22nd Century Group (XXII) reported significant progress under CEO James A. Mish’s leadership in a recent shareholder update. Over the past year, shares have surged by 470%. The company is advancing its Modified Risk Tobacco Product (MRTP) application for the VLN® brand, which could allow for marketing claims of containing '95% Less Nicotine.' Additionally, strategic partnerships in the hemp/cannabis sector and a new Canadian subsidiary are expected to enhance growth. The company aims to capitalize on regulatory changes in tobacco and cannabis markets, with a total addressable market of $1.3 trillion.

22nd Century Group, Inc. (XXII) announced the successful completion of a registered direct offering, selling 10 million shares at $4.00 per share, yielding gross proceeds of $40 million. This capital infusion aims to support various strategic objectives across its plant franchises, including R&D expenses, capital expenditures, and commercialization efforts. The company is positioned to capitalize on recent initiatives in its hemp/cannabis franchise and anticipates continued momentum leading to the launch of its reduced nicotine tobacco product in the near future.

22nd Century Group (NYSE: XXII) announced its inclusion in the Russell 2000®, Russell 3000®, and Russell Global Indexes, effective June 28, 2021. This milestone is seen as a recognition of the company's growth and the confidence in its leadership. The firm aims to leverage its strengths in plant science to address the $1.3 trillion market opportunity across tobacco, hemp/cannabis, and a third plant-based franchise. The inclusion is expected to enhance visibility for investors in the tobacco harm reduction and hemp research sectors.

22nd Century Group (XXII) has announced strategic partnerships with leading plant breeders and a collaboration with Aurora Cannabis to enhance its hemp/cannabis initiatives. The company has established a Canadian subsidiary to expand its operations and aims to monetize its biosynthesis intellectual property in late 2021. A $40 million registered direct offering is expected to support growth initiatives. The firm is positioned to capitalize on stable cannabinoid levels in cannabis plants and is actively pursuing multiple revenue streams in its cannabis franchise.

22nd Century Group (NYSE American: XXII) announced a definitive agreement to sell 10 million shares at $4.00 each, totaling $40 million in gross proceeds. The offering targets strategic objectives, including research and development, capital expenditures, and commercialization. The financing, set to close around June 9, 2021, is facilitated by Cowen and Company, LLC. The net proceeds will support the company's plant franchises and its mission to reduce tobacco harm and enhance hemp/cannabis offerings.